Justin Bergner of Gabelli and Gina Sanchez of Chantico Global set the scene for what may lie ahead for the markets in 2026, both risks and rewards.

US price cuts, Medicare expansion, and new oral GLP-1 approvals reshape the competitive outlook for weight-loss drugs.

There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...

Rocket Pharmaceuticals is a Buy, with strong catalysts, undervalued programs, and significant upside. Click here to read my ...

Kevin projects the top 10 fantasy baseball dynasty outfielders going into the 2029 MLB season. His top MLB outfielders to ...

The Federal Reserve has officially shifted gears. By lowering interest rates in mid-December 2025, the Fed sent a decisive ...